/day results in a mean steady-state serum concentration (C ss ) of 731 pg/mL ± 163 pg/mL that is achieved within a day. 5 The mean area under the time versus concentration curve (AUC 0-28 ) is 19,659 ± 4,413 days•pg/mL, with a clearance of 22.3 ± 5.0 L/ day/m 2 . 5 The volume of distribution (V d ) is 1.61 ± 0.74 L/m 2 . The serum elimination half-life (t ½ ) is 1.250 ± 0.634 hours. 5 The short serum half-life and relatively high clearance suggest that blinatumomab is renally excreted. 5 The metabolism of blinatumomab has not been identified. 4 Selected therapeutic regimens for blinatumomab administration are listed in Table 1 .
PREPARATION

A. Follow institutional policies for preparation of
hazardous medications when preparing blinatumomab. B. Blinatumomab should be prepared in a nonpolyvinyl chloride (PVC) container. C. Add 5.5 mL of the solution stabilizer to 250 mL 0.9% sodium chloride (NS), and mix gently. D. Reconstitute the blinatumomab vial with 3 mL preservative-free sterile water for injection to a final concentration of 12.5 mcg/mL. E. Inject the sterile water slowly down the side of the vial to avoid excessive foaming. F. Dilute the drug in the NS solution previously prepared (step C above). ; pyrexia (all grades) 62% to 100%, [6] [7] [8] (grade 1 or 2) 53%, 3 (grade 3 or 4) 4% to 7%. 
STABILITY
DOSAGE MODIFICATIONS
A. Hepatic: There are no recommended dose adjustments for hepatic dysfunction due to lack of pharmacokinetic studies in patients with hepatic impairment.
4
B. Renal: There are no recommended dose adjustments for renal dysfunction due to lack of pharmacokinetic studies in patients with renal impairment.
MECHANISM OF ACTION
Pembrolizumab is a humanized monoclonal antibody with activity against the inhibitory programmed death receptor-1 (PD-1) found on T cells. Binding of the PD-1 receptor to PD-1 ligands (PD-L1 and PD-L2) on the surface of tumor cells suppresses cytotoxic T-cell proliferation and cytokine release. Pembrolizumab inhibits this interaction by binding to PD-1 receptors, thus inhibiting interaction with the PD-1 ligands and impeding PD-1 pathway-mediated anti-tumor immune response.
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PHARMCOKINETICS
An IV dose of pembrolizumab 2 mg/kg produced an area under the concentration versus time curve at steady state (AUC 0-21 ) of 0.643 g•day/L with a coefficient of variation (CV%) of 37%. 11 Following a single IV dose of pembrolizumab 3 mg/kg, the AUC 0-28 was 90 μg•day/mL with a mean CV% of 23%.
14 The clearance of pembrolizumab is 0.22 L/day based on doses of 1 to 10 mg/kg IV given every 2 weeks or 2 to 10 mg/kg IV given every 3 weeks. 13 The mean CV% elimination serum half-life (t ½ ) was 26 days (24%). 13 Selected therapeutic regimens for pembrolizumab administration are listed in Table 2 . 
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Name: Pembrolizumab
Cancer Chemotherapy Update B. Pembrolizumab should be infused through a low protein-binding, 0.2-micron to 5-micron filter.
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TOXICITIES
Most of the toxicities listed below are presented according to their degree of severity. Higher grades represent more severe toxicities. Although there are several grading systems for cancer chemotherapy toxicities, all are similar. One of the frequently used systems is the National Cancer Institute Common Terminology Criteria for Adverse Events (http://evs. nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_ QuickReference_8.5x11.pdf). Oncologists generally do not adjust doses or change therapy for grade 1 or 2 toxicities; but they make, or consider making, dosage reductions or therapy changes for grade 3 or 4 toxicities. Incidence values are rounded to the nearest whole percent unless incidence was less than or equal to 0.5%. A. Cardiovascular: Dehydration (all grades) 1%, 11 face edema (all grades) 2%, 11 hypertension (all grades) 5%, 12 peripheral edema (all grades) 5%.
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B. Central Nervous System: Confusion (grade 3 or 4) 1%, 11 dizziness (all grades) 2%, 11 encephalopathy (grade 3 or 4) 1%, 11 headache (all grades) 5%. 11, 12 C. Constitutional: Asthenia (all grades) 6%
; chills (all grades) 5% to 8% 11, 12 ; fatigue (all grades) 9% to 33%, 11, 12 (grade 3 or 4) 6%
; influenzalike illness (all grades) 1% 11 ; lethargy (all grades) 5%
; night sweats (all grades) 5% 11 ; pain (all grades) 2% 11 ; pyrexia (all grades) 3%
; tumor pain (all grades) 1%. ; erythema (all grades) 5% 11, 12 ; pigmentation disorder (all grades) 2%
; pruritus (all grades) 18% to 26%, 11, 12 (grade 3 or 4) 5%
12
; rash (all grades) 14% to 18%, 11, 12 ; hypothyroidism (all grades) 5% to 6% 11, 12 ; thyroxine decreased (all grades) 1%
11
; weight decreased (all grades) 3%.
F. Eye Disorders: Dry eye (all grades) 2%, 11 visual impairment (all grades) 2% to 5%. 11, 12 G. Gastrointestinal: Abdominal discomfort (all grades) 2%, 11 abdominal pain (all grades) 1% to 3%, 11, 12 constipation (all grades) 5%, 11 decreased appetite (all grades) 5% to 9%, 11, 12 diarrhea (all grades) 11% to 27%, 11, 12 dysgeusia (all grades) 5%, 12 gastroesophageal reflex disease (all grades) 3%, 11 11, 12 ; autoimmune hepatitis (grade 3 or 4) 1%. ; pneumonitis (all grades) 2%, 11 (grade 3 or 4) 1%.
K. Musculoskeletal: Arthralgia (all grades) 5% to 12% 11, 12 ; back pain (all grades) 3%
; muscle spasms (all grades) 2% to 5% 11, 12 ; muscular weakness (any grade) 3%, 11 (grade 3 or 4) 1% 11 ; myalgia (all grades) 5% to 6% 11, 12 ; pain in extremity (all grades) 5% 12 ; pain in jaw (all grades) 1%. 
